🔎 Trials Near Me

Hjem › Blodkreft › Texas › Dallas

Kliniske studier for Blodkreft i Dallas, TX

12 studier for Blodkreft søker deltakere på steder i og rundt Dallas (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.

Offisiell studietekst (engelsk)

Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

RekruttererFase 3
  • Texas Oncology-Baylor Sammons Cancer Center ( Site 0062), Dallas
Alder 18 og eldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT03486873

Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)

RekruttererFase 2
  • UT Southwestern-Harold C. Simmons Cancer Center ( Site 2730), Dallas
Alder 18 og eldre · Alle kjønn · Oppdatert 24. sep. 2026 · NCT04728893

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

RekruttererFase 1
  • UT Southwestern Simmons Cancer Center - RedBird, Dallas
  • UT Southwestern/Simmons Cancer Center-Dallas, Dallas
Alder 18 og eldre · Alle kjønn · Oppdatert 23. sep. 2026 · NCT03816345

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

RekruttererFase 1/2
  • Baylor Scott & White Health, Dallas
Alder 12 og eldre · Alle kjønn · Oppdatert 3. sep. 2026 · NCT04588922

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

RekruttererFase 3
  • Texas Oncology-Presbyterian Cancer Center, Dallas
Alder 18 og eldre · Alle kjønn · Oppdatert 20. aug. 2026 · NCT07007312

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

RekruttererFase 1
  • Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas
Alder 18 og eldre · Alle kjønn · Oppdatert 20. aug. 2026 · NCT06001788

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

RekruttererObservasjonsstudie
  • Medical City Dallas, Dallas
  • Children's Medical Center Dallas, Dallas
Alle aldre · Alle kjønn · Oppdatert 6. jul. 2026 · NCT01351545

Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

RekruttererFase 1
  • UT Southwestern Medical Center, Dallas
Alder 18 og eldre · Alle kjønn · Oppdatert 15. jun. 2026 · NCT02074839

A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients

RekruttererFase 3
  • Medical City Dallas Hospital, Dallas
  • UT Southwestern/Simmons Cancer Center-Dallas, Dallas
Alder 2 til 18 · Alle kjønn · Oppdatert 5. mai 2026 · NCT05711667

Exercise Program (TEAM Me) for the Improvement of Movement and Mobility in Pediatric and Adolescent and Young Adult Patients With Cancer Undergoing a Blood Stem Cell Transplant

Rekrutterer
  • UT Southwestern/Simmons Cancer Center-Dallas, Dallas
Alder 6 til 29 · Alle kjønn · Oppdatert 4. mai 2026 · NCT04678427

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

RekruttererFase 1
  • UT Southwestern - Simmons Cancer Center, Dallas
Alder 18 og eldre · Alle kjønn · Oppdatert 13. mar. 2026 · NCT05735184

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

RekruttererFase 1
  • University of Texas, Southwestern, Dallas
Alder 1 til 21 · Alle kjønn · Oppdatert 6. des. 2024 · NCT05476770

Blodkreft-studier i andre byer

Andre studier i Dallas

Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.